CLAIMS

What is claimed is:

1. A pharmaceutical composition for chronic wound healing, comprising the following three components: (1) an anti-inflammatory agent which is acteoside, (2) an astringent which is bismuth subgallate, and (3) a cooling agent which is borneol, and optionally combined with one or more pharmaceutically acceptable carriers; wherein an equivalent ratio of the three components (1) the anti-inflammatory agent: (2) the astringent: (3) the cooling agent is 1:0.1-10:0.1-10.

2. The pharmaceutical composition of claim 1, wherein the chronic wound is a diabetic wound.

3. The pharmaceutical composition of claim 1, wherein the equivalent ratio of the three components (1) the anti-inflammatory agent: (2) the astringent: (3) the cooling agent is 1:0.5-5:0.5-5.

4. The pharmaceutical composition of claim 1, comprising (1) 0.05%-10% of acteoside, (2) 0.05%-10% of bismuth subgallate, (3) 0.02%-5% of borneol by weight and the pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4, comprising (1) 0.1%-5% of acteoside, (2) 0.06%-6% of bismuth subgallate, (3) 0.03%-3% of borneol by weight and the pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5, comprising (1) 0.3%-5% of acteoside, (2) 0.5%-5% of bismuth subgallate, (3) 0.5%-1% of borneol by weight and the pharmaceutically acceptable carrier.

7. Use of a pharmaceutical composition according to any of claims 1 to 6 in the preparation of a medicament for treating a chronic wound.

8. The use of claim 7, wherein the chronic wound is a diabetic wound.

9. The pharmaceutical composition of claim 1, further comprising a suitable excipient for the preparation of an external pharmaceutical form, a cosmetic form or a medicinal material form.